YHYayoi Honda

Yayoi Honda

*This is an algorithmically generated author record based on publicly available information.

Yayoi Honda has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and toxicity of palbociclib in heavily treated patients with metastatic breast cancer

    by Naoko Iwamoto, Tomoyuki Aruga, Katsumasa Kuroi, Chiaki Saita, Mai Onishi, Risa Goto, Toshiyuki Ishiba, Yayoi Honda, Hiromi Miyamoto

    Background: Palbociclib is reported to improve progression-free survival (PFS) in patients with estrogen-receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC). However, evidence of the effects of palbociclib in heavily treated patients is limited. The present study aimed to determine the effects and toxicity of palbociclib in heavily pretreated patients and to find the differences between the patients treated with palbociclib in upfront line and those with in later-line. Methods: This retrospective, single-center, observational study enrolled 26 patients with ER-positive, HER2-negative MBC who started palbociclib (125 mg) plus endocrine therapy between December 2017 and July 2018. These patients were divided into 2 groups, upfront (<3) and later-line groups (≥4 lines prior therapy). Progression-free survival (PFS) estimated using the Kaplan-Meier method was compared between 14 patients who received upfront-line therapy and 12 who received later-line therapy. Results: Among the 26 patients, 22 (85%) had visceral metastasis. The median number of prior treatment lines for MBC was 3.5 and the median follow-up was 5.1 months. Median PFS was 3.6 months in later-line group, and PFS was significantly shorter than in the upfront-line group (p = 0.046, median PFS: not reached in upfront line group). The incidences of grade 3/4 neutropenia were 86% and 83% in the upfront- and later-line groups, respectively. One patient developed febrile neutropenia. The treatment schedule was interrupted in 13 (93%) and 11 (92%) patients in the upfront- and later-line groups, respectively. The number of the patients who required dose reduction was higher in later-line group than upfront-line group (67% vs. 57%). Conclusion: Although the toxicity of palbociclib is tolerable with a low incidence of febrile neutropenia, palbociclib is less-effective for heavily pretreated patients in comparison with lightly-pretreated patients. Our findings indicated that palbociclib could be used as a front-line treatment for MBC.


  • Evaluation of Stereotactic Vacuum-Assisted Breast Biopsy for Microcalcifications Diagnosed as Category 3

    by Naoko Iwamoto, Tomoyuki Aruga, Mai Ohnishi, Risa Goto, Kazumi Horiguchi, Yayoi Honda, Hiromi Miyamoto, Shinichiro Horiguchi

    マンモグラフィのカテゴリー3(C-3)石灰化症例におけるステレオガイド下吸引式組織生検(ST-VAB)の結果を検討する。2005年1月から2017年4月に当院で施行したST-VAB 症例のうちC-3の石灰化を有する287症例289病変を後方視的に検討した。 ST-VAB 結果は,良性194例,悪性69例(浸潤癌11例,非浸潤癌58例),良悪性鑑別困難26例であった。良性と悪性では石灰化の形状と分布に差は認められなかった。悪性では55歳以上の割合が高く(χ 二乗検定p=0.02),乳房造影MRI 検査(以下MRI)で造影域を認めた症例が多かった(χ 二乗検定p=0.0001)。ST-VAB で非浸潤癌の診断で手術を施行した55例のうち,術後病理診断で浸潤部を認めた症例は13例(24%)であった。51例でセンチネルリンパ節生検が行われ,すべて転移陰性であった。 55歳以上でMRI 検査において造影所見を有する症例ではST-VAB の適応と考えられる。一方,今回の検討結果から良性が大部分を占めること,悪性であっても非浸潤癌が80%であることが明らかとなった。閉経前でMRI でも造影所見を認めない症例では,即時にST-VAB を行わず,経過観察でも妥当性があると思われた。

  • Open Access

    Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved

    by Chiaki Saita, Risa Goto, Tomoyuki Aruga, Nami Idera, Yayoi Honda, Kazumi Horiguchi, Hiromi Miyamoto, Shinichiro Horiguchi, Toshinari Yamashita, Katsumasa Kuroi

    Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy.


  • Management of bone metastasis in the patients achieved 10-year survival with recurrence from breast cancer

    by Kazumi Horiguchi, Risa Goto, Nami Idera, Yayoi Honda, Hiromi Miyamoto, Tomoyuki Aruga, Toshinari Yamashita, Katsumasa Kuroi

    Background: According to the progression of treatment for the breast cancer, it has become possible to attain long-term survival in some cases of the metastatic breast cancer patients. We investigated about the patients with bone metastasis achieved long survival in our hospital.

  • Open Access

    Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications

    by Yayoi Honda, Tomoyuki Aruga, Toshinari Yamashita, Hiromi Miyamoto, Kazumi Horiguchi, Dai Kitagawa, Nami Idera, Risa Goto, Katsumasa Kuroi

    The prognosis of breast cancer-derived brain metastasis is poor, but new drugs and recent therapeutic strategies have helped extend survival in patients. Prediction of therapeutic responses and outcomes is not yet possible, however. In a retrospective study, we examined prognostic factors in patients with breast cancer-derived brain metastasis, and we tested the prognostic utility of a breast cancer-specific Graded Prognostic Assessment in these patients. Sixty-three patients diagnosed with brain metastasis from breast cancer treated surgically and adjuvantly were included. We examined clinical variables per primary tumor subtype: ER+/HER2− (luminal), HER2+ (human epidermal growth factor receptor type 2-enriched) or ER−/PR−/HER2− (triple negative). We also categorized patients' breast cancer-specific Graded Prognostic Assessment scores and analyzed post-brain metastasis survival time in relation to these categories. The breast cancers comprised the following subtypes: luminal, n = 18; human epidermal growth factor receptor type 2-enriched, n = 27 and triple-negative, n = 18; median survival per subtype was 11, 37 and 3 months, respectively. Survival of human epidermal growth factor receptor type 2-enriched patients was longer, though not significantly (P = 0.188), than that of luminal patients. Survival of triple-negative patients was significantly short (vs. human epidermal growth factor receptor type 2-enriched patients, P < 0.001). Karnofsky performance status, HER2 status and the disease-free interval (from initial treatment to first recurrence) were shown to be significant prognostic factors (Karnofsky performance status < 70: relative risk 2.08, P = 0.028; HER2+: relative risk 2.911, P = 0.004; disease-free interval < 24 months: relative risk 1.933, P = 0.011). Breast cancer-specific Graded Prognostic Assessment scores reflected disease-free intervals and survival times. Our data indicate that breast cancer-specific Graded Prognostic Assessment-based prediction will be helpful in determining appropriate therapeutic strategies for patients with brain metastasis from breast cancer.


    • 1 June 2012
      • Vol. 39  (6) , 1013-6

    [A case of primary breast cancer responding to pre-operative chemotherapy with the combination of paclitaxel and carboplatin for ovarian cancer].

    by Dai Kitagawa, Yurie Nako, Yayoi Honda, Takashi Shigekawa, Kazumi Horiguchi, Tomoyuki Aruga, Toshinari Yamashita, Katsumasa Kuroi

    A 62-year-old woman was diagnosed with primary left breast cancer during a follow-up for an ovarian tumor. She had at first undergone surgical resection of an ovarian tumor, and a pathological examination had revealed ovarian cancer. Gynecologists decided to treat her ovarian cancer with chemotherapy, and we were initially planning to provide treatment for breast cancer after that was completed. Sentinel lymph node biopsy performed before chemotherapy revealed no axillary metastases. The patient received six courses of intravenous PTX (175 mg/m2 on day 1, every 3 weeks) and intravenous CBDCA (AUC6 on day 1, every 3 weeks) as combination therapy. Abdominal lymph node dissection was performed between chemotherapy courses 3 and 4. The lump in the left breast showed partial clinical response, and partial resection of the left breast was performed after completion of chemotherapy. In Japan, few cases of primary breast cancer treated preoperatively using carboplatin-containing regimens have been described.